Filing Flows › 8-K events › Tempest Therapeutics
Tempest Therapeutics: departure or appointment of directors and officers
Form 8-K filed Oct 30, 2026 · items 5.02
What the filing says
Departure of Chief Financial Officer and Principal Financial and Accounting Officer Constance Ames confirmed to Tempest Therapeutics, Inc. (the “Company”) that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions she holds with the Company for personal
Read the filing on SEC EDGAR →
What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →
What this kind of filing means
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
Tempest Therapeutics’s other material 8-Ks
Other recent cfo changes
- Karbon-X Nov 6, 2026
- Power Solutions International Nov 6, 2026
- Audax Private Credit Fund, LLC Nov 6, 2026
- Audax Credit BDC Nov 6, 2026
- Blaize Holdings Nov 5, 2026
- Valion Bio Nov 5, 2026
- Digital Turbine Nov 5, 2026
- TransUnion Nov 5, 2026
- Teads Holding Nov 5, 2026
- Novelis Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.